A Hong Kong Phase II trial reported outcomes from point-of-care, locally manufactured CD19 CAR-T cells produced in 14 days for six children with leukemia. The study reported complete remission in all treated patients, with manageable toxicity. The result emphasizes a manufacturing acceleration model that aims to shrink the time window between enrollment and dosing—an operational constraint that can be critical in pediatric hematologic malignancies. The trial used locally produced CAR-T at a production timeline designed for bedside logistics. For the CAR-T field, the key takeaway is not only efficacy but feasibility of a short-cycle manufacturing approach in a pediatric population, where access delays can otherwise limit treatment. Further details on durability, neurotoxicity profiles, and bridging therapies are likely to be the next questions for regulators and adopting centers.